Vibegron (also known as KRP-114V; MK-4618; trade name Gemtesa) is a novel and potent β3 adrenergic receptor agonist approved in 2020 for the treatment of overactive bladder, which is a condition in which the bladder muscles contract uncontrollably and cause frequent urination.

纯度：≥98%

CAS：1190389-15-1